Low faecal haemoglobin concentration potentially rules out significant colorectal disease

Colorectal Disease

Volumn 15, Issue 3, 2013, Pages

  Mcdonald, P J ^a   Digby, J ^a   Innes, C ^b   Strachan, J A ^a   Carey, F A ^b   Steele, R J C ^b   Fraser, C G ^b  

^a King's Cross Hospital   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Colorectal disease; Diagnostic accuracy; Faecal immunochemical test; Predictive value; Sensitivity; Specificity

Indexed keywords

HEMOGLOBIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER RISK; COLORECTAL ADENOMA; COLORECTAL DISEASE; DIAGNOSTIC ACCURACY; ENTERITIS; FAMILY HISTORY; FECES ANALYSIS; FECES LEVEL; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECTUM HEMORRHAGE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLONIC DISEASES; COLONOSCOPY; FECES; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MASS SCREENING; MIDDLE AGED; RECTAL DISEASES; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84874393542     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12087     Document Type: Article

References (30)

1. Manz M, Burri E, Rothen C et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol 2012; 12: 5.
2. Kok L, Elias SG, Witteman BJM, Goedhard JG, Muris JW, Moons KG, de Wit NJ. Diagnostic accuracy of point-of-care fecal calprotectin and immunochemical occult blood tests for diagnosis of organic bowel disease in primary care: the Cost-effectiveness of a Decision Rule for Abdominal Complaints in Primary Care (CEDAR) study. Clin Chem 2012; 58: 69-98.
3. Ayling RM. New faecal tests in gastroenterology. Ann Clin Biochem 2012; 49: 44-54.
4. SIGN (2011) Diagnosis and Management of Colorectal Cancer. SIGN, Edinburgh. http://www.sign.ac.uk/pdf/sign126.pdf (accessed 30 June 2012).
5. Goddard AF, James MW, McIntyre AS, Scott BB, on behalf of the British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60: 1309-16.
6. NICE (2011) CG131. Colorectal Cancer - the Diagnosis and Management of Colorectal Cancer. NICE, London. http://guidance.nice.org.uk/CG131 (accessed 30 June 2012).
7. Fraser CG. Faecal occult blood tests - eliminate, enhance or update? Ann Clin Biochem 2008; 45: 117-21.
8. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-9.
9. Fraser CG, Digby J, McDonald PJ, Strachan JA, Carey FA, Steele RJC. Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel screening programme. J Med Screen 2012; 19: 8-13.
10. Logan RFA, Patnick J, Nickerson C, Coleman L, Rutter MD, Von Wagner C, on behalf of the English Bowel Cancer Screening Evaluation Committee. Outcomes of the Bowel Screening Programme (BCSP) in England after 1 million tests. Gut 2012; 61: 1439-46.
11. Fraser CG. Fecal occult blood tests. Life savers or outdated colorectal screening tools? Clin Lab News 2011; 37: 8-10.
12. Young GP, Fraser CG, Halloran SP, Cole S. Guaiac-based faecal occult blood testing for colorectal cancer screening - an obsolete strategy? Gut 2012; 61: 959-60.
13. Halloran SP, Launoy G, Zappa M. (2010) Faecal occult blood testing. In: European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis, 1st edition (eds Segnan J, Patnick L, von Karsa L), pp. 103-14. International Agency for Research on Cancer, Publications Office of the European Union, Luxembourg
14. Rabeneck L, Rumble RB, Thompson F et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012; 26: 131-47.
15. Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ, de Vet HC. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. BMJ 2010; 340: c1269.
16. Bossuyt PM, Reitsma JB, Bruns DE et al. for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Chem 2003; 49: 1-6.
17. Fraser CG, Allison JE, Halloran SP, Young GP, on behalf of the Expert Working Group on Fecal Immunochemical Tests for Hemoglobin, Colorectal Cancer Screening Committee, World Endoscopy Organization. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 2012; 104: 810-4.
18. Atkin WS, Saunders BP. Surveillance guidelines after removal of colorectal adenomatous polyps. Gut 2002; 51 (Suppl v): v6-vv9.
19. Fraser CG. Screening for colorectal neoplasia with faecal tests. Lancet Oncol 2011; 12: 516-7.
20. McDonald PJ, Strachan JA, Digby J, Steele RJC, Fraser CG. Faecal haemoglobin concentrations by gender and age: implications for population-based screening for colorectal cancer. Clin Chem Lab Med 2012; 50: 935-40.
21. van Dam L, Kuipers EJ, van Leerdam ME. Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol 2010; 24: 479-92.
22. Fraser CG, Allison JE, Young GP, Halloran SP. Newer fecal tests: opportunities for professionals in laboratory medicine. Clin Chem 2012; 58: 963-5.
23. NICE (2011) CG122. The Recognition and Initial Management of Ovarian Cancer. NICE, London. http://guidance.nice.org.uk/CG122. (accessed 30 June 2012).
24. Allison JE, Fraser CG, Halloran SP, Young GP. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology 2012; 142: 422-4.
25. Omata F, Shintani A, Isozaki M, Masuda K, Fujita Y, Fukui T. Diagnostic performance of quantitative fecal immunochemical test and multivariate prediction model for colorectal neoplasms in asymptomatic individuals. Eur J Gastroenterol Hepatol 2011; 23: 1036-41.
26. Yeoh K-G, Ho K-Y, Chiu H-M. The Asia-Pacific Colorectal Screening score: a validated tool that stratifies risk for colorectal advanced neoplasia in asymptomatic Asian subjects. Gut 2011; 60: 1236-41.
27. Fraser CG. A future for faecal haemoglobin measurements in the medical laboratory. Ann Clin Biochem 2012; 49: 518-26.
28. Marshall T, Lancashire R, Sharp D, Peters TP, Cheng KK, Hamilton W. The diagnostic performance of scoring systems to identify symptomatic colorectal cancer compared to current referral guidance. Gut 2011; 60: 1242-8.
29. Hippisely-Cox J, Coupland C. Identifying patients with suspected colorectal cancer in primary care: derivation and validation of an algorithm. Br J Gen Pract 2012; 62: e29-37.
30. Collins GS, Altman DG. Identifying patients with undetected colorectal cancer, an independent validation of QCancer (Colorectal). Br J Cancer 2012; 107: 260-5.